GO
Loading...

Actavis Inc

More

  • *Wendel, Nordic Capital hand in final bids- sources. Nordic Capital may be looking to combine LTS Lohmann with another skin patch maker it agreed to buy last month, Acino. The sources said that Japan's Hisamitsu Pharmaceutical and private equity house EQT were no longer being considered as suitors by LTS Lohmann's owners, which include drug major Novartis.

  • Amgen to buy Onyx for more than $10 billion Monday, 26 Aug 2013 | 7:51 AM ET

    Amgen has struck a $10 billion-plus deal to buy Onyx Pharmaceuticals, ending a two-month-long auction for the cancer drugmaker.

  • Delivering Alpha: 2012's best and worst ideas Friday, 28 Jun 2013 | 9:36 AM ET

    Hedge fund titan Leon Cooperman came up with 10 ideas last year and all of the stocks have delivered returns. Will anybody at this year's Delivering Alpha conference match his record?

  • The report card on hedge fund boss Leon Cooperman Thursday, 27 Jun 2013 | 12:23 PM ET
    Leon Cooperman, chairman of Omega Advisors

    Check out last year's top 10 picks from Omega Advisors founder Leon Cooperman and guess what you find? A 31 percent return.

  • Cramer: Big Winners to Gain into Quarter's End? Thursday, 20 Jun 2013 | 6:29 PM ET

    As the quarter draws to a close, Jim Cramer thinks 5 stocks could attract new buyers.

  • Cramer Makes the Case for M&A Monday, 17 Jun 2013 | 6:58 PM ET

    Cramer gives three reasons why companies should consider mergers and acquisitions.

  • High Court's Generic Drug Ruling 'a Holy Mess' Monday, 17 Jun 2013 | 3:58 PM ET
    Supreme Court Justice Stephen Breyer

    A Supreme Court decision gives the FTC the go-ahead to continue suing drug makers over deals that delay generic versions from being sold.

  • Two Global Companies Just Moved for Tax Reasons Wednesday, 22 May 2013 | 5:41 AM ET

    Even as Apple faced a grilling from lawmakers over its tax avoidance schemes, two more companies revealed they would move jurisdictions to lighten their tax burden.

  • Stocks End Lower; Dow, S&P Briefly Hit New Highs Monday, 20 May 2013 | 4:27 PM ET

    Stocks closed slightly lower in choppy trading Monday, pulling back after the Dow and S&P 500 hit fresh all-time highs and amid ongoing worries that the Federal Reserve may taper its bond-purchase program.

  • Futures Slide Amid Fed Easing Fears Monday, 20 May 2013 | 8:48 AM ET

    U.S. stock market index futures were slightly lower Monday, after major averages finished higher for the fourth-consecutive week, amid ongoing concerns the Federal Reserve may begin to taper off its quantitative easing program sooner than expected.

  • Actavis to Buy Warner Chilcott for $8.5 Billion Monday, 20 May 2013 | 8:11 AM ET
    Warner Chilcott Ltd.'s acne treatment Doryx.

    Generic drugmaker Actavis will buy specialty pharmaceuticals company Warner Chilcott in a stock deal valued at about $8.5 billion.

  • Early Movers: WMT, KSS, CSCO & More Thursday, 16 May 2013 | 7:33 AM ET

    Some of the names on the move ahead of the open.

  • Actavis Rejects $15 Billion Bid From Mylan: Report Wednesday, 15 May 2013 | 7:43 AM ET

    Actavis received and rejected a takeover offer from Mylan last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation said.

  • Early Movers: DIS, DKS, ANF & More Monday, 29 Apr 2013 | 7:35 AM ET

    Some of the names on the move ahead of the open.

  • Merger of Drugmakers Valeant, Actavis on Hold: Source Sunday, 28 Apr 2013 | 10:50 AM ET

    A proposed merger of Valeant Pharmaceuticals International Inc and Actavis Inc. was put on hold after the two drugmakers failed to agree on terms of a deal.

  • Early Movers: Insurers, NDAQ, AAPL & More Tuesday, 2 Apr 2013 | 8:01 AM ET

    Some of the names on the move ahead of the open.

  • High Court Weighs Drug Companies' Generics Policy Monday, 25 Mar 2013 | 9:49 AM ET

    Federal regulators are pressing the Supreme Court to stop big pharmaceuticals from paying generic drug competitors to delay releasing cheaper versions of brand-name drugs.

  • US Supreme Court Will Hear 'Pay for Delay' Drug Case Friday, 22 Mar 2013 | 9:17 AM ET
    The U.S. Supreme Court building.

    The Supreme Court will hear arguments on Monday over whether big drug companies can settle patent litigation with generic rivals by making deals to keep cheaper products off the market.

  • Watson begins shipping generic diabetes drug Friday, 26 Oct 2012 | 5:39 PM ET

    The Parsippany, N.J.- based company had sued the FDA this summer to gain approval for the drug and sought shared marketing exclusivity for its generic version of the drug. After Watson sued the FDA, the company said Mylan Pharmaceuticals Inc. intervened as a defendant in the action.

  • Mylan at long-time high on outlook, deal talk Friday, 26 Oct 2012 | 3:30 PM ET

    NEW YORK-- Shares of Mylan Inc. rose to their highest price in almost nine years on Friday after the drugmaker reported higher sales of its EpiPen allergy injection and raised its 2012 guidance. The company said it now expects to earn between $2.50 and $2.60 per share in 2012, about 15 cents per share more than it had expected.

Most Popular Video

Thursday, 17 Apr 2014 | 4:13 PM ET

Dissecting today's market activity and the current state of financials, with Yra Harris, Praxis Trading partner; Larry Glazer, Mayflower Advisors; CNBC contributor Carol Roth; "Fast Money" Guy Adami and CNBC's Kate Kelly.

Thursday, 17 Apr 2014 | 5:46 PM ET

CNBC voice over talent Jim Birdsall shares the top 5 sayings from traders on "Fast Money" over the years.

Thursday, 17 Apr 2014 | 6:40 PM ET

Mad Money's Jim Cramer reflects on CNBC's evolution over the past 25 years.